Summary
Johnson & Johnson reported strong revenue growth for the nine months ended September 30, 2007, with worldwide sales increasing by 13.9% to $45.1 billion. This growth was significantly driven by the acquisition of Pfizer Inc.'s Consumer Healthcare business, which contributed 7.3% to the overall sales increase. The company also saw positive impacts from currency fluctuations, particularly in international markets. Despite the revenue growth, net earnings for the nine months decreased to $8.2 billion from $8.9 billion in the prior year, largely due to significant restructuring charges of $745 million announced in the third quarter. These charges impacted profitability, particularly in the Pharmaceutical and Medical Devices & Diagnostics segments. The company continues to manage a complex legal and regulatory environment, with ongoing litigation related to product liability, patent disputes, and government investigations, though management believes these will not materially adversely affect the company's financial position.
Key Highlights
- 1Total sales for the first nine months of 2007 increased by 13.9% to $45.1 billion, driven significantly by the acquisition of Pfizer's Consumer Healthcare business (+7.3%).
- 2Net earnings for the nine months decreased to $8.2 billion from $8.9 billion in the prior year, impacted by $745 million in restructuring charges.
- 3The Consumer segment experienced robust growth of 48.2% for the nine months, primarily due to the Pfizer acquisition.
- 4The Pharmaceutical segment saw a 6.7% sales increase for the nine months, with notable performance from Remicade and Topamax, though generic competition impacted Duragesic and hormonal contraceptives.
- 5The Medical Devices and Diagnostics segment grew sales by 5.8% for the nine months, with strong performance in DePuy and LifeScan, but faced challenges in the Cordis franchise due to the drug-eluting stent market contraction.
- 6Operating cash flow increased to $10.9 billion for the nine months, up from $10.0 billion in the prior year.
- 7The company is managing significant legal and regulatory challenges, including ongoing product liability cases and investigations, while maintaining confidence in its ability to manage potential liabilities.